Endovascular Engineering (E2) has received a pair of FDA clearances for its pulmonary embolism treatment platform, spanning its dual-action thrombectomy system and hardware that returns filtered blood to the patient. The Hēlo system combines continuous vacuum aspiration with physical agitation to help break up the blood clot. Its catheter starts with a lower-profile, 15-French design […]
Endovascular Engineering (E2)
AngioDynamics alleges patent infringement by E2 over clot removal technology
AngioDynamics has filed a lawsuit against Endovascular Engineering (E2) in the U.S. District Court for the District of Delaware. Latham, New York-based AngioDynamics alleges that E2 infringes on patents for its AngioVac and AlphaVac blood clot removal systems. AngioVac and AlphaVac, two FDA-approved thrombectomy systems, work to remove blood clots (thrombi and emboli) from veins. […]
E2 raises $80M Series C for Hēlo thrombectomy system
Endovascular Engineering (E2) announced today that it raised $80 million in an oversubscribed Series C financing round. Gilde Healthcare and Norwest co-led the latest financing for the Menlo Park, California-based company. Existing investors, including Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, M&L Healthcare Investments, also participated. Two existing undisclosed strategic investors and a new […]
E2 raises $42M Series B to advance clot removal tech
Endovascular Engineering (E2) announced today that it raised $42 million in an oversubscribed Series B financing round. 415 Capital and S3 Ventures co-led the financing round. Panakès Partners, M&L Healthcare and founding investor Santé Ventures also participated. Two global strategic investors made commitments alongside Cordis, which continues its strategic partnership with E2. With the funding, […]
E2 has positive data for its Hēlo thrombectomy system
Endovascular Engineering (E2) today announced positive safety and feasibility results from a clinical trial of its Hēlo PE thrombectomy system. The company presented positive safety and feasibility results at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions. It simultaneously published the results in JSCAI. Menlo Park, California-based E2’s ENGULF trial is a […]
Cordis among those investing $15M in Endovascular Engineering
Endovascular Engineering today announced the closing of a $15 million Series A1 financing co-led by Santé Ventures and Cordis. The Menlo Park, California–based startup is also called E2. It’s focused on developing advanced mechanical thrombectomy technology. Get the full story on our sister site Medical Tubing + Extrusion.
